Business Wire

LIFESPIN-GMBH

13.12.2021 09:02:20 CET | Business Wire | Press release

Share
Lifespin GmbH Secures €2.5M Bridge Financing to Further Build its AI-Enabled Metabolomics-Based Differential Diagnosis Panel for Neurological Diseases

Lifespin GmbH, a deep data company currently developing a proprietary AI-based health testing platform to measure quantitative metabolic data in patient samples, has secured €2.5M bridge financing to fuel the company’s continued product development.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211213005059/en/

The Lifespin platform is based on mapping metabolomics for human health and translating that data into health information that can be deployed in a wide range of pharmaceutical, research, and clinical settings. Lifespin’s health diagnostics software will be applicable in the broader healthcare space ranging from diagnostics to patient stratification and personalized medicine, as well as supporting the drug discovery process.

“We are very excited about Lifespin’s growth trajectory with a platform solution which can be accessed by collaborating clinical laboratories and drug discovery partners and scale globally via our cloud solutions,” said Lifespin’s CEO, Dr. Ali Tinazli.

The bridge financing will be used to continue the development of the first diagnostics panel for neurological diseases such as multiple sclerosis and Parkinson’s disease, some of which cannot be addressed with legacy laboratory-based methods. The first commercial test of the differential diagnostics panel will be covering early stages of multiple sclerosis. The panel will be further expanded with other neurological indications over time.

“Lifespin’s new software-based approach to digitally capture, compare and analyze human metabolomes will open up a new and exciting field, complementary to existing health diagnostics,” said Robert Wieland, Managing Director of Wieland Capital and Lifespin’s lead investor.

Lifespin expects to begin fundraising for a Series A in 2022 to fund its first product introductions and to support expanding its business operations to the United States.

# # #

Lifespin (www.lifespin.ai ) is a deep data company that maps human health based on metabolomics. Lifespin’s advisory board consists of key opinion leaders such as James Rothman (Nobel Laureate in Physiology/Medicine, Sterling Professor of Cell Biology, Yale University, New Haven, CT USA) and numerous industry veterans. We have standardized the baseline for human health and can detect distinct deviations caused by diseases. A pathogenesis impacts metabolism, causing specific changes in the presence and quantity of metabolites. Our proprietary technology platform quantitatively captures individual metabolomes, i.e., up to hundreds of metabolite concentrations with a single Nuclear Magnet Resonance (NMR) measurement. Lifespin is building a proprietary in-house biobank with currently 200,000 human blood samples and performing quantitative in-house measurements of metabolomes for systematic mapping across health conditions. Our constantly growing proprietary database of digitized metabolic profiles enables the analysis of billions of metabolic relationships. Digital metabolic profiles enable differential diagnosis for the early detection of health conditions, staging of diseases, monitoring of treatment success and personalized medicine. Our first regulatory approved Software-as-IVD will be for the early differential diagnosis of multiple sclerosis and is expected in 2022. This will be followed by other tests for the detection of neurological, cancer, and inflammatory diseases. Our cloud-based business model is built on our proprietary Software-as-a-Service (SaaS) platform for diagnostics and health information and is globally scalable.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Brings Flagship Kinexions Conference to India, Showcasing Growing Market Momentum17.11.2026 02:30:00 CET | Press release

Inaugural event features leaders from Tata Consumer Products and Sun Pharma, highlighting India's growing role in global supply chain innovation Kinaxis® Inc. (TSX: KXS), a global leader in end-to-end supply chain planning and orchestration, today opened its first-ever Kinexions India conference in Mumbai, highlighting the company's growing presence in the country and India's importance to its global innovation and customer delivery operations. With teams in Chennai and Bangalore supporting product development, engineering, professional services and customer success, India plays an important role in Kinaxis' global operations. The company continues to invest in research and development in India, strengthening its engineering and innovation capabilities to support the next generation of AI and supply chain orchestration technologies. "India plays an important role in how we innovate and support customers around the world," said Razat Gaurav, CEO of Kinaxis. "Bringing Kinexions here for

Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa16.11.2026 22:30:00 CET | Press release

European Commission approval based on data from Phase 3 STOP-HS1 and STOP-HS2, which showed that Povofortay® (povorcitinib) met the primary endpoint at Week 12 and delivered clinically meaningful, durable responses through Week 54 and was well tolerated 1,2 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Povofortay® (povorcitinib) 45 mg and 75 mg for the treatment of eligible adults with moderate to severe hidradenitis suppurativa (HS). “The European Commission approval of Povofortay marks an important milestone for Incyte, advancing a key growth driver for our business and bringing a new treatment option to people living with HS, a chronic and often debilitating disease,” 2,3 said Bill Meury, Chief Executive Officer, Incyte."As the first and only once-daily oral treatment approved in the European Union for eligible adults with moderate to severe HS, Povofortay gives physicians an important new option for their patients.” The approval is based on res

Moody’s Names Timothy Bhatt as Chief Information Officer16.11.2026 22:00:00 CET | Press release

Bhatt to lead enterprise technology strategy, AI deployment, and cyber and information security in Executive Leadership Team role Moody’s Corporation (NYSE: MCO) announced today that it has named Tim Bhatt to the newly created role of Chief Information Officer (CIO), effective December 7th, and that he will join the company’s Executive Leadership Team. Mr. Bhatt, who has served as Chief Technology Officer (CTO) of Moody’s Ratings since 2018, will also continue in that role. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116893391/en/ Timothy Bhatt, Chief Information Officer, Moody's As CIO, Mr. Bhatt will lead Moody’s enterprise technology strategy, AI enablement, and information security, with responsibility for the company’s technology services and operations and cybersecurity teams. He will further modernize how Moody’s operates, bringing together human expertise, trusted data and AI agents to reimagine enterprise work

Lattice Extends Space Heritage with On-Orbit Milestone in TESAT Optical Communication Terminals16.11.2026 22:00:00 CET | Press release

Radiation-resilient Lattice Nexus FPGAs have operated as specified in TESAT optical communication terminals since 2025 Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced that its low power, radiation-resilient Lattice Nexus™ FPGAs have surpassed one year of on-orbit operation in TESAT optical communication terminals. Since launch, the FPGAs have delivered consistent performance in the demanding application of space-based laser communication at 10 Gbps, adding to Lattice’s space heritage of thousands of FPGAs launched to date. TESAT has flown optical communication terminals on GEO and LEO missions for more than a decade, supplying broadband constellations and institutional programs. For the redesign of its terminal electronics, Lattice Nexus FPGAs addressed TESAT’s requirements for radiation tolerance, low power, and board footprint. Built on 28 nm fully depleted silicon-on-insulator (FD-SOI) process technology, the Nexus platf

New Holiday Data From Xsolla Shows Players Are Shopping, Gifting, and Choosing Brands Inside Video Games16.11.2026 18:00:00 CET | Press release

New Survey of More Than 4,000 Players Finds 78% Play More During the Holidays and 82.5% Would Watch a Rewarded Ad in Exchange for a Bonus Offer Xsolla (USA), Inc., a global commerce company, today announced a new data and insights report on how players shop, spend, and respond to brands during the holiday season. Titled “Why Video Games Belong in Your Holiday Commerce Strategy,” the report draws on direct answers from more than 4,000 players, gathered through opt-in rewarded surveys on Xsolla Offerwall. Players chose to take part and received a reward for sharing, which makes the data first-party and consent-based. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111104582/en/ Graphic: Xsolla The research builds on the conversation Xsolla opened at Advertising Week New York 2026 about how brands can reach players in more ways through video games. Combined with Xsolla’s insights into in-game purchasing behavior across an aud

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye